KR930702979A - Endo-N- (8-methyl) -8-azabicyclo in the treatment of dependence and withdrawal syndrome [3. 2. 1] Oct-3-yl) -2,3-dihydro-3,3 dimethylindole-1-carboxamide - Google Patents

Endo-N- (8-methyl) -8-azabicyclo in the treatment of dependence and withdrawal syndrome [3. 2. 1] Oct-3-yl) -2,3-dihydro-3,3 dimethylindole-1-carboxamide

Info

Publication number
KR930702979A
KR930702979A KR1019930701141A KR930701141A KR930702979A KR 930702979 A KR930702979 A KR 930702979A KR 1019930701141 A KR1019930701141 A KR 1019930701141A KR 930701141 A KR930701141 A KR 930701141A KR 930702979 A KR930702979 A KR 930702979A
Authority
KR
South Korea
Prior art keywords
substance
abuse
azabicyclo
endo
carboxamide
Prior art date
Application number
KR1019930701141A
Other languages
Korean (ko)
Inventor
폴 브랙버언 토마스
존 존스 브라이언
Original Assignee
데이빗 로버츠
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909022537A external-priority patent/GB9022537D0/en
Priority claimed from GB919112236A external-priority patent/GB9112236D0/en
Application filed by 데이빗 로버츠, 비이참 그루우프 피이엘시이 filed Critical 데이빗 로버츠
Publication of KR930702979A publication Critical patent/KR930702979A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

효과적 비독성양의 인돌린 유도체(예, 엔도-N-(8-메틸-8-아자비시클로[3,2,1]옥트-3-일)-2,3-디히드로-3,3-디메틸인돌-1-카르복스아미드) 또는 이의 계약학적으로 허용가능한 염 또는 용매화합물을 투염함으로 구성되는 사람을 포함한 포유동물에 있어서 남용 약제 또는 물질의 탐닉으로 초래되는 금단 증후군의 경감 또는 예방 및/또는 남용 약제 또는 물질에 대한 의존의 억제를 위한 방법.Effective non-toxic amounts of indolin derivatives (eg endo-N- (8-methyl-8-azabicyclo [3,2,1] oct-3-yl) -2,3-dihydro-3,3-dimethyl Reduction or prevention and / or abuse of withdrawal syndrome resulting from indulgence of an abuse agent or substance in a mammal, including a person consisting of indole-1-carboxamide) or a contractually acceptable salt or solvate thereof A method for suppressing dependence on a drug or substance.

Description

의존 및 금단 증후군의 치료에 있어 엔도-N-(8-메틸)-8-아자비시클로[3,2,1]옥트-3-일)-2,3-디히드로-3,3-디메틸인돌-1-카르복스아미드의 사용Endo-N- (8-methyl) -8-azabicyclo [3,2,1] oct-3-yl) -2,3-dihydro-3,3-dimethylindole- in the treatment of dependence and withdrawal syndrome Use of 1-carboxamide

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

사람을 포함한 포유 동물에 있어서 남용 약제 또는 물질 탐닉으로 초래되는 금단 증후군의 경감 또는 예방 및/또는 남용 약제 또는 물질에 대한 의존, 억제를 위한, 사기 처리가 용구되는 포유 동물에게 효과적 비독성 양의엔도-N-(8-메틸-8-아자비시클로[3,2,1]옥트-3-일)-2,3-디히드로-3,3-디메틸인돌-1-카르복스아미드 또는 이의 제약학적으로 허용가능한 염 또는 용매화합물을 투여함으로 구성되는 방법Non-toxic amounts of endo -effects effective in mammals subject to fraudulent treatment for the reduction or prevention of withdrawal syndrome and / or dependence on, or inhibition of, abuse drugs or substance addiction in humans, including mammals -N- (8-methyl-8-azabicyclo [3,2,1] oct-3-yl) -2,3-dihydro-3,3-dimethylindol-1-carboxamide or a pharmaceutical thereof Method comprising administering an acceptable salt or solvate 제 1항에 있어서, 남용 약제 또는 물질이 코카인인 방법.The method of claim 1, wherein the abuse agent or substance is cocaine. 제1항에 있어서, 남용 약제 또는 물질이 벤조디아제핀인 방법The method of claim 1 wherein the abuse agent or substance is benzodiazepine. 사람을 포함한 포유 동물에 있어 남용 약제 또는 물질의 탐닉으로 초래되는 금단 증후군의 경감 또는 예방 및/또는 남용 약제 또는 물질에 대한 의존의 억제를 위한 약물의 제조에 있어서엔도-N-(8-메틸-8-아자비시클로[3,2,1]옥트-3-일)-2,3-디히드로-3,3-디메틸인돌-1-카르복스아미드 또는 이의 제약학적으로 허용가능한 염 또는 용매화물의 사용 Endo -N- (8-methyl- Use of 8-azabicyclo [3,2,1] oct-3-yl) -2,3-dihydro-3,3-dimethylindol-1-carboxamide or a pharmaceutically acceptable salt or solvate thereof 제4항에 있어서, 남용 약제 또는 물질이 코카인인 사용.5. Use according to claim 4, wherein the abuse agent or substance is cocaine. 제 4항에 있어서, 남용 약제 또는 물질이 벤조디아제핀인 사용.5. Use according to claim 4, wherein the abuse agent or substance is benzodiazepine. 효과적양의엔도-N-(8-메틸-8-아자비시클로[3,2,1]옥트-3-일)-2,3-디히드로-3,3-디메틸인돌-1-카르복스아미드 또는 이의 제약학적으로 허용가능한 염 또는 용매화물 및 제약학적 부형제로 구성되는, 사람을 포함한 포유 동물에 있어서 남용 약제 또는 물질의 탐닉으로 초래되는 금단 증후군의 경감 또는 예방 및/또는 남용 약제 또는 물질에 대한 의존의 억제를 위한 제약학적 조성물.Effective amount of endo- N- (8-methyl-8-azabicyclo [3,2,1] oct-3-yl) -2,3-dihydro-3,3-dimethylindol-1-carboxamide or Reliance on or prevention of withdrawal syndrome and / or dependence on abuse drugs or substances in a mammal, including humans, consisting of pharmaceutically acceptable salts or solvates and pharmaceutical excipients thereof Pharmaceutical compositions for the inhibition of. 제 7항에 있어서, 남용 약제 또는 물질이 코카인인 조성물.8. The composition of claim 7, wherein the abuse agent or substance is cocaine. 제 7항에 있어서, 남용 약제 또는 물질이 벤조디아제핀인 조성물.8. The composition of claim 7, wherein the abuse agent or substance is benzodiazepine. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930701141A 1990-10-17 1991-10-17 Endo-N- (8-methyl) -8-azabicyclo in the treatment of dependence and withdrawal syndrome [3. 2. 1] Oct-3-yl) -2,3-dihydro-3,3 dimethylindole-1-carboxamide KR930702979A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909022537A GB9022537D0 (en) 1990-10-17 1990-10-17 Novel treatment
GB9022537.6 1990-10-17
GB9112236.3 1991-06-07
GB919112236A GB9112236D0 (en) 1991-06-07 1991-06-07 Novel treatment
PCT/GB1991/001811 WO1992006689A1 (en) 1990-10-17 1991-10-17 USE OF ENDO-N-(8-METHYL-8-AZABICYCLO[3.2.1]oct-3-yl)-2,3-DIHYDRO-3,3DIMETHYLINDOLE-1-CARBOXAMIDE IN THE TREATMENT OF DEPENDENCE AND WITHDRAWAL SYNDROME

Publications (1)

Publication Number Publication Date
KR930702979A true KR930702979A (en) 1993-11-29

Family

ID=26297808

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701141A KR930702979A (en) 1990-10-17 1991-10-17 Endo-N- (8-methyl) -8-azabicyclo in the treatment of dependence and withdrawal syndrome [3. 2. 1] Oct-3-yl) -2,3-dihydro-3,3 dimethylindole-1-carboxamide

Country Status (7)

Country Link
EP (1) EP0553160A1 (en)
JP (1) JPH06501946A (en)
KR (1) KR930702979A (en)
AU (1) AU8728591A (en)
CA (1) CA2094157A1 (en)
IE (1) IE913621A1 (en)
WO (1) WO1992006689A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687980T2 (en) * 1986-01-07 1993-06-17 Beecham Group Plc INDOLDER DERIVATIVES WITH AN AZABICYCLIC SIDE CHAIN, METHOD FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND PHARMACEUTICAL COMPOSITIONS.
DE3777805D1 (en) * 1986-11-21 1992-04-30 Glaxo Group Ltd MEDICINES FOR TREATING OR PREVENTING THE WITHDRAWAL SYNDROME.
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment

Also Published As

Publication number Publication date
WO1992006689A1 (en) 1992-04-30
JPH06501946A (en) 1994-03-03
IE913621A1 (en) 1992-04-22
CA2094157A1 (en) 1992-04-18
EP0553160A1 (en) 1993-08-04
AU8728591A (en) 1992-05-20

Similar Documents

Publication Publication Date Title
US3773955A (en) Analgetic compositions
JP2765845B2 (en) Remedies for prevention of discontinuation syndrome
PL324988A1 (en) Orally administered readily dissolving compositions for dopamine antagonists
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
EP0663401A4 (en) Morphinan derivative and medicinal use.
TR200003666T2 (en) Formoterol for the prevention, treatment of an acute case of asthma
EP0715855A3 (en) NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
KR970009799A (en) Treatment of substance abuse withdrawal
KR970706815A (en) Oral Compositions Containing Ondansetron
KR930702000A (en) Use of parosetin for the treatment of old age dementia, edema, migraine headaches, or poor food
KR850004389A (en) Method for preparing physiologically active agent with enhanced percutaneous penetration
KR900005978A (en) Antimalarial Compositions and Methods of Treatment Using Kininidine, Artemisinin and Derivatives thereof
GR3029666T3 (en) Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
KR870008886A (en) 2-alkoxy-N- (1-azabicyclo [2,2,2] oct-3-yl) benzamide and thiobenzamide
PT1027053E (en) METHOD OF PREVENTION OF NEFROTOXICITY CAUSED BY CYCLOSPORINS AND TACROLIMUS
KR920000326A (en) Use of GM₁monosialogangliosides and their internal ester derivatives in humans to prevent the development of resistance to the analgesic effects of morphine and homologues in humans
RU94045866A (en) Use of bis-phenylalkylpiperazines for treatment of disorders caused by substance abuse, method of treatment
KR930702979A (en) Endo-N- (8-methyl) -8-azabicyclo in the treatment of dependence and withdrawal syndrome [3. 2. 1] Oct-3-yl) -2,3-dihydro-3,3 dimethylindole-1-carboxamide
KR970701047A (en) ANTITUSSIVE COMPOSITION CONTAINING AN ANTITUS SIVE AND BENZYDAMINE
Montgomery et al. Placebo-controlled efficacy of antidepressants in continuation treatment
KR970701191A (en) Heterocyclic compounds
NO307496B1 (en) Use of a <parta> opioid antagonist for the preparation of an antitussive agent
Neal et al. Ketanserin and pirenperone attenuate acute morphine withdrawal in rats
Zegveld et al. Domperidone in the Treatment of Postoperatve Vomiting: A Double-Blind Multicenter Study

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid